glp-1 · pharma
What Are the GLP-1 Creator Disclosure Rules for Brand Teams
What our team has seen across the DTC-pharma GLP-1 cohort. Ozempic, Mounjaro, Wegovy creator-deal patterns. Off-label risk, compounded-drug exposure, the FDA September 2025 crackdown, and the rules brands need before signing the next deal.
Hims and Hers has shipped 60 creator deals on its combined channel since January 2025, with 26 named creators in our tracking.
Tim Chantarangsu (4.21M subs) has run 6 deals between December 2025 and February 2026 alone.
Most of those reads include weight-loss messaging.
Some include the GLP-1 brand category by name.
That is the line where the deal stops being a wellness read and starts carrying FDA exposure.
The risk is not the drug. The risk is the script.
Novo Nordisk did not pay creators for Ozempic posts. Eli Lilly did not pay creators for Mounjaro posts. Neither brand has a direct creator deal in our database. The brand-safety problem still happened because telehealth brands prescribing the drug, or pharmacies compounding it, pulled creators in.
That is the gap this post fills.
Where am I writing this from
Our database tracks 387 DTC-pharma creator deals across BlueChew, Keeps, Hims and Hers, and Curology.
It tracks zero direct deals with Novo Nordisk, zero with Eli Lilly, zero with Wegovy, zero with Ozempic, zero with Mounjaro.
It tracks zero direct deals with the named compounded-GLP-1 brands the FDA called out in September 2025: no Mochi, no Sequence, no Eden, no Plushcare in the data.
That is the asymmetry that makes GLP-1 the highest-risk category in regulated influencer marketing.
The drug-maker does not pay creators. The telehealth brand or compounding pharmacy does. The creator does not always know which layer of the stack they are reading for.
Here is the GLP-1 brief-review pass we run before any weight-loss read ships.
The GLP-1 creator deal shape
Most GLP-1 creator reads route through one of three brand types.
Type one. The DTC telehealth brand with a prescribing relationship. Hims and Hers, Ro, Forhers. They prescribe FDA-approved branded GLP-1s on subscription. These reads get the most regulatory review.
Type two. The compounded-GLP-1 pharmacy or marketplace. Mochi, Sequence, Eden, Henry Meds. They sell compounded semaglutide or tirzepatide. The FDA's September 2025 letter list targeted this category.
Type three. Wellness-adjacent brands that mention GLP-1s as comparison. Weight Watchers and Noom. They do not prescribe. They mention. The mention itself is the risk.
The first 12 to 14 seconds of any read in these three types decide the exposure.
Verdict: three brand types, one risk.
Off-label and compounded-drug risk
Ozempic and Mounjaro are FDA-approved for type-2 diabetes. Wegovy and Zepbound are the same active ingredients approved for weight loss.
A creator who says "I started on Ozempic and lost 20 pounds" makes two errors at once. First, an off-label weight-loss claim for Ozempic. Second, a specific clinical outcome the brand cannot prove for influencer-grade claims.
The same creator saying "I started on Wegovy" carries the on-label claim but still owes the risk-language block, the cleared-claims library, and the prescribing-information pointer.
Compounded GLP-1s carry a third risk. The FDA's September 2025 letter to 30 telehealth companies named compounded-GLP-1 marketing as the trigger. The agency's GLP-1 supply update is the policy backdrop. Compounded promotion carries higher warning-letter risk than on-label branded promotion.
That sequence catches creator deals off guard.
Where this gets real
We have seen brand teams sign a 6-figure GLP-1 deal with a creator and only catch the off-label or compounded layer after recording. The fix costs the brand a re-shoot, a takedown, and 6 to 8 weeks of legal back-and-forth. Our 9 percent on creator spend includes a pre-clearance pass that catches the off-label claim before the camera turns on. Your regulatory team gets a script they can mark up, not a fire to put out.
The September 2025 FDA crackdown
The FDA sent letters to 30 telehealth and compounding companies between July and September 2025.
The agency's enforcement statement lists three core violations: misleading efficacy claims, missing risk information, and promotion of compounded versions as if FDA-approved.
NextMed paid a related FTC settlement in December 2025 for deceptive GLP-1 weight-loss claims. Both moves landed on the brand, not the creator. The creators kept their fees.
In our tracking, the on-label DTC cohort (BlueChew, Hims and Hers, Keeps, Curology) has not drawn an OPDP letter on a creator post. The compounded-GLP-1 cohort (visible in the FDA's letter list, not in our database) did.
Pre-clearance and on-label discipline separates the rebookable program from the warning-letter list.
Verdict: pre-clearance pays for itself.
Here is the on-label vocabulary library we keep for GLP-1 reads.
What the disclosure actually looks like
A compliant GLP-1 creator read on a telehealth brand carries five elements.
One. The benefit claim. From the brand's pre-cleared messaging library. No specific clinical outcomes the brand cannot prove.
Two. The risk block. Common side effects (nausea, vomiting, diarrhea). Serious risks tied to the label (thyroid C-cell tumors, pancreatitis, gallbladder issues). Eight to twelve seconds, in the read, at the same volume as the benefit claim.
Three. The prescribing-information pointer. A spoken line, an on-screen banner, or a description link to the full prescribing information.
Four. The eligibility frame. Who the medicine is for and who it is not for. Age, BMI, pregnancy, contraindications.
Five. The disclosure of the paid relationship. Spoken in the first 30 seconds, on-screen overlay matching the spoken line, repeated near any call-to-action.
A read that ships four of these and skips the risk block is the most common warning-letter pattern.
A read that ships all five is the rebookable read. Here is the five-element GLP-1 read checklist we hand to creators before recording.
What keeps the brand out of the letter queue
Brands in our database that survive review keep a four-piece file on every creator deal.
The signed brief, dated before recording. The cleared-claims library, version-numbered. The approved script and final cut, date-stamped. The risk-language placement notes with timecodes.
If OPDP sends a letter, that file is the first request. Brands with the file get a manageable cease-and-desist. Brands that cannot show the paper trail get the warning letter and the consent decree.
The compounded-GLP-1 category is the one to watch in 2026. The next warning-letter wave will land on telehealth and pharmacy brands, not on Novo Nordisk or Eli Lilly directly.
The creator program is the surface the agency sees. The brief is what protects it.
Verdict: brief signed, brand safe.
Where We Come In
[generated, not legal-reviewed] Built from our team's experience across the DTC-pharma cohort in our database. Not legal advice. Big Pharma is out of scope: our database has zero direct deals with Novo Nordisk, Eli Lilly, or other drug manufacturers. The patterns describe DTC telehealth brands prescribing GLP-1s and the compounded category named in the FDA's September 2025 letter list.
We write the brief, route it to your regulatory team, get it signed before recording, and audit risk-language placement before publish. We catch off-label claims before recording.
The cost lives inside our 9 percent on creator spend. If your regulatory team rejects the brief, we pull the creator and refund.
For the fair-balance layer, see pharma creator FDA fair-balance rules. For the FTC frame, see telehealth FTC compliance.
Speak with us if you want the GLP-1 brief template before your next deal.
Further reading from our database:
- Hub: Telehealth influencer marketing in 2026. The 90-day pilot plan and Meta ad rule changes.
- Cross link: Telehealth FTC compliance. The four FTC rules and the 5-clause brief.
- Cross link: Telehealth medical claims language rules. The five-word vocabulary that survives review.
- Risk shield: Pharma creator FDA fair-balance rules. The OPDP frame the brief sits inside.
Frequently Asked Questions
Can a creator promote Ozempic, Wegovy, or Mounjaro directly?
Only through a brand that holds the prescribing relationship, with the FDA fair-balance risk language inside the read. Most creator promotion in this category is for telehealth brands that prescribe the drug, not the drug manufacturer.
What is a compounded GLP-1 and why is it riskier for creators?
A compounded GLP-1 is a pharmacy-made version of semaglutide or tirzepatide. The FDA's September 2025 letter to 30 telehealth companies named compounded-GLP-1 marketing as the trigger. Brands promoting compounded versions carry higher warning-letter risk.
Did Novo Nordisk or Eli Lilly pay creators directly?
Not in our database. Across our deal tracking, Eli Lilly's appearances are all medical-conference sponsorships (CBS Mornings, Economist Impact Events, CDHFtube), not creator marketing. Novo Nordisk has zero direct creator deals on file. The brand-safety problem still happened because creators talked about the drugs unpaid.
What does the disclosure actually need to say?
A common-side-effects line, a serious-risk line tied to the label (thyroid C-cell tumors, pancreatitis, gallbladder issues), a pointer to the full prescribing information, and no claim outside the cleared messaging library. Eight to twelve seconds, in the read, not in the description.
Is this post legal advice?
No. It is what our team has seen across the DTC-pharma GLP-1 cohort. This is generated content, not legal-reviewed. Your brand's regulatory counsel signs off on the final brief.
Frequently asked
Can a creator promote Ozempic, Wegovy, or Mounjaro directly?
Only through a brand that holds the prescribing relationship, with the FDA fair-balance risk language inside the read. Most creator promotion in this category is for telehealth brands that prescribe the drug, not the drug manufacturer.
What is a compounded GLP-1 and why is it riskier for creators?
A compounded GLP-1 is a pharmacy-made version of semaglutide or tirzepatide. The FDA's September 2025 letter to 30 telehealth companies named compounded-GLP-1 marketing as the trigger. Brands promoting compounded versions carry higher warning-letter risk.
Did Novo Nordisk or Eli Lilly pay creators directly?
Not in our database. Across our deal tracking, Eli Lilly's appearances are all medical-conference sponsorships (CBS Mornings, Economist Impact Events, CDHFtube), not creator marketing. Novo Nordisk has zero direct creator deals on file. The brand-safety problem still happened because creators talked about the drugs unpaid.
What does the disclosure actually need to say?
A common-side-effects line, a serious-risk line tied to the label (thyroid C-cell tumors, pancreatitis, gallbladder issues), a pointer to the full prescribing information, and no claim outside the cleared messaging library. Eight to twelve seconds, in the read, not in the description.
Is this post legal advice?
No. It is what our team has seen across the DTC-pharma GLP-1 cohort. This is generated content, not legal-reviewed. Your brand's regulatory counsel signs off on the final brief.